More than half of treated patients got infected.

These are oncology’s costliest therapies, and infection risk decides who can safely receive them.

Redirecting T-cells against tumors also strips the defenses that keep ordinary pathogens out, a 2,192-patient database analysis found.

The unedited manuscript flags residual confounding, so its late-onset infection gap needs confirmation.

Sources: Nature